Excitement was kept under firm control at the launch of the first UK drug for Alzheimer’s disease. For a lucky few it is certainly beneficial, but as potential demand is so huge, financial and ethical issues must be faced. Robert Short describes the effects and efficacy of donepezil (Aricept).
Author/s: Robert Short
For the full article please see the PDF download linked to the right. The full JDC archive is available if you subscribe.